Reuters logo
BRIEF-GlaxoSmithKline starts phase III study with Mepolizumab in patients with severe Hypereosinophilic syndrome
March 31, 2017 / 10:42 AM / 8 months ago

BRIEF-GlaxoSmithKline starts phase III study with Mepolizumab in patients with severe Hypereosinophilic syndrome

March 31 (Reuters) - GlaxoSmithKline:

* GSK starts phase III study with Mepolizumab in patients with severe Hypereosinophilic syndrome Source text for Eikon:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below